Zogenix Stock

Zogenix Financial Leverage

Delisted

The Financial Leverage (Equity Multiplier) of Zogenix (ZGNX) as of Aug 6, 2026 is 2.62. In the previous year, Financial Leverage (Equity Multiplier) was 1.76 — a change of 48.61% (higher).

Financial Leverage

2.62

YoY

48.61%

Last updated:

Financial Leverage (Equity Multiplier) of Zogenix is 2026 2.62 . Financial Leverage (Equity Multiplier) of Zogenix was 2025 1.76 . It decreases by 48.61% higher compared to the previous year.
Access this data via the Eulerpool API

Zogenix Stock analysis

What does Zogenix do? Zogenix Inc. is an American biotech company that specializes in the development and commercialization of drugs for the treatment of central nervous system disorders and pain. The company was founded in 2006 and is headquartered in Emeryville, California. In 2009, Zogenix Inc. brought its first product to market, the prescription painkiller Zohydro. Shortly after, in 2012, the company announced the approval of Sumavel DosePro, an innovative injection technology for the treatment of migraines. In 2018, the company completed a merger with California-based Modis Therapeutics. Together, they are developing drugs for rare genetic metabolic disorders. Zogenix has a promising business model, focusing on research and development and the marketing of true innovations in the CNS and pain field. The company aims to revolutionize the medical market with its medications, rather than simply replacing existing drugs. For this reason, Zogenix collaborates closely with leading institutes and research facilities to identify and develop new active ingredients. Zogenix is divided into various business segments, each specializing in the development of new drugs and therapies. One of Zogenix's main products is the Sumavel DosePro injection technology, which allows for quick and effective treatment of migraine attacks. Another important business area for Zogenix is the development of medications and therapies for the treatment of neuropsychiatric disorders. This includes ZX008 (Fenfluramine), an investigational drug for the treatment of Dravet syndrome, a rare form of epilepsy. The medication has already been approved in Europe and is currently being reviewed in the United States. Zogenix also focuses on the development of therapies for opioid and opiate-related disorders, as well as pain management. This includes the product Zohydro, which is a long-acting opioid painkiller. Zogenix offers a variety of prescription drugs and therapies targeting various neurological disorders and pain syndromes. The company's products aim to alleviate symptoms and address the underlying causes of the diseases. In summary, Zogenix is a biotech company specializing in the development and commercialization of drugs for the treatment of central nervous system disorders and pain. With a wide range of products and a promising business model, the company is focused on innovation in the medical industry. Zogenix Inc represents an important area of research and development for new medications in the future. Zogenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zogenix stock

Financial Leverage (Equity Multiplier) of Zogenix is 2.62 in 2026.

Financial Leverage (Equity Multiplier) of Zogenix changed from 1.76 to 2.62, representing a 48.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Zogenix since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Zogenix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Zogenix

All Key Metrics — Zogenix